Hoskins et al developed a prognostic model for patients with diffuse large cell lymphoma treated with MACOP-8. This can help identify patients who may benefit from more aggressive or novel therapy. The authors are from the Cancer Control Agency and University of British Columbia in Vancouver, British Columbia.
Patient selection: diffuse large cell lymphoma
MACOP-8 (8 drugs: doxorubicin, cyclophosphamide, vincristine, bleomycin, methotrexate, cotrimoxazole, ketoconazole)
Parameters (present at diagnosis):
(1) B symptoms (night sweats, fever, unexplained weight loss)
(2) number of lymph node sites/groups involved
(3) number of extranodal sites involved
(4) age of the patient in years
Parameter |
Finding |
Points |
B symptoms |
absent |
0 |
|
present |
1 |
number of lymph node groups involved |
<= 2 |
0 |
|
>= 3 |
1 |
number of extranodal sites involved |
<= 1 |
0 |
|
>= 2 |
1 |
age of the patient |
<= 60 years of age |
0 |
|
> 60 years of age |
1 |
where:
• The first 3 items relate to tumor burden.
• Age relates to the patient's ability to tolerate chemotherapy.
total number of risk factors present =
= SUM(points for all 4 parameters)
Interpretation:
• minimum number of risk factors: 0
• maximum number of risk factors: 4
• The higher the score the greater the 5 year mortality rate.
simple predictive model for 5 year survival in percent =
= MIN(100, 30 * (4 - (total number of risk factors)))
Specialty: Hematology Oncology